SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
This rule would go beyond already controversial genetically modified organisms (GMOs) to encompass hundreds of new products of new gene and genome editing techniques. (Photo: Andrea Seaman/flickr/cc)
If the proposed rule becomes law, USDA will write a letter like this:
Dear Biotechnology Product Developer,
We write in response to your request that we affirm the validity of your self- determination that your GE product complies with USDA rules authorized by the Plant Protection Act. We grant your request. You may sell your product in the U.S. and in foreign countries, once you have received grants of self-determination validity from the Food and Drug Administration and the Environmental Protection Agency.
(FDA and EPA rules for self-determination will come all too soon.)
Unfortunately, this scenario is not science fiction, but the very likely result of USDA's proposed rule, if it is finalized. The deadline for public comment on the rule is August 5. IATP opposed the rule in a July 30 letter for several reasons, including:
USDA, in its desire to maximize trade in GE crops as soon as possible and everywhere, has proposed a rule that would make it exceedingly difficult to assess a GE plant's risks, even for the "unfamiliar products" that are targeted for USDA paperwork review, when GE product developers decide not to self-determine their compliance with the rule to increase acceptance of their products by foreign regulators in U.S. export targets . The classification of commercial applicant studies and data as "confidential business information" adds to a proposed rule that, as Professor Kuzma writes, "does not inspire public confidence."
Trump and Musk are on an unconstitutional rampage, aiming for virtually every corner of the federal government. These two right-wing billionaires are targeting nurses, scientists, teachers, daycare providers, judges, veterans, air traffic controllers, and nuclear safety inspectors. No one is safe. The food stamps program, Social Security, Medicare, and Medicaid are next. It’s an unprecedented disaster and a five-alarm fire, but there will be a reckoning. The people did not vote for this. The American people do not want this dystopian hellscape that hides behind claims of “efficiency.” Still, in reality, it is all a giveaway to corporate interests and the libertarian dreams of far-right oligarchs like Musk. Common Dreams is playing a vital role by reporting day and night on this orgy of corruption and greed, as well as what everyday people can do to organize and fight back. As a people-powered nonprofit news outlet, we cover issues the corporate media never will, but we can only continue with our readers’ support. |
If the proposed rule becomes law, USDA will write a letter like this:
Dear Biotechnology Product Developer,
We write in response to your request that we affirm the validity of your self- determination that your GE product complies with USDA rules authorized by the Plant Protection Act. We grant your request. You may sell your product in the U.S. and in foreign countries, once you have received grants of self-determination validity from the Food and Drug Administration and the Environmental Protection Agency.
(FDA and EPA rules for self-determination will come all too soon.)
Unfortunately, this scenario is not science fiction, but the very likely result of USDA's proposed rule, if it is finalized. The deadline for public comment on the rule is August 5. IATP opposed the rule in a July 30 letter for several reasons, including:
USDA, in its desire to maximize trade in GE crops as soon as possible and everywhere, has proposed a rule that would make it exceedingly difficult to assess a GE plant's risks, even for the "unfamiliar products" that are targeted for USDA paperwork review, when GE product developers decide not to self-determine their compliance with the rule to increase acceptance of their products by foreign regulators in U.S. export targets . The classification of commercial applicant studies and data as "confidential business information" adds to a proposed rule that, as Professor Kuzma writes, "does not inspire public confidence."
If the proposed rule becomes law, USDA will write a letter like this:
Dear Biotechnology Product Developer,
We write in response to your request that we affirm the validity of your self- determination that your GE product complies with USDA rules authorized by the Plant Protection Act. We grant your request. You may sell your product in the U.S. and in foreign countries, once you have received grants of self-determination validity from the Food and Drug Administration and the Environmental Protection Agency.
(FDA and EPA rules for self-determination will come all too soon.)
Unfortunately, this scenario is not science fiction, but the very likely result of USDA's proposed rule, if it is finalized. The deadline for public comment on the rule is August 5. IATP opposed the rule in a July 30 letter for several reasons, including:
USDA, in its desire to maximize trade in GE crops as soon as possible and everywhere, has proposed a rule that would make it exceedingly difficult to assess a GE plant's risks, even for the "unfamiliar products" that are targeted for USDA paperwork review, when GE product developers decide not to self-determine their compliance with the rule to increase acceptance of their products by foreign regulators in U.S. export targets . The classification of commercial applicant studies and data as "confidential business information" adds to a proposed rule that, as Professor Kuzma writes, "does not inspire public confidence."